Revised policy for therapies for COVID-19

Having trouble viewing this email? View it as a Web page.

Health Care Authority (HCA) logo

Apple Health (Medicaid) Provider Alert

Attention providers

What changed?
The Health Care Authority (HCA) has updated its COVID-19 therapies policy with information regarding new COVID-19 monoclonal antibodies.

New COVID-19 monoclonal antibodies
Retroactive for dates of service on and after February 11, 2022, providers may bill HCA for the following monoclonal antibody treatments:

HCPC code Short Description
Q0222 Bebtelovimab 175 mg
M0222 Bebtelovimab injection
M0223 Bebtelovimab injection home

See Therapies for COVID-19 for more information regarding the policy and procedure codes involved.

COVID-19 Fee Schedule
HCA revised the COVID-19 Fee Schedule. See HCA’s Provider billing guides and fee schedules, under COVID-19.